XO1 Limited is a virtual biopharmaceutical company focused on developing ichorcumab, an innovative antibody targeting thrombin to provide anticoagulation without the risk of bleeding. The company operates in the biopharmaceutical sector, primarily serving healthcare providers and patients who require anticoagulation therapy. XO1's business model revolves around the research and development of this unique therapeutic solution, which aims to address a significant unmet medical need. Revenue is generated through partnerships, licensing agreements, and eventual product sales. The market for anticoagulation therapies is substantial, given the prevalence of conditions like deep vein thrombosis and pulmonary embolism, which require effective and safe anticoagulation treatments. XO1's acquisition by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, underscores the strategic value and potential impact of its core product, ichorcumab.

Keywords: biopharmaceutical, ichorcumab, thrombin, anticoagulation, bleeding, healthcare, therapy, research, development, acquisition.